Sofalcone Derivatives as TxA2 Antagonists Without Bleeding Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiplatelet therapies, such as aspirin, have limitations including gastrointestinal side effects and counteracting effects on vascular endothelial cells, while existing TxA2 receptor antagonists are not widely used due to potency issues, highlighting the need for novel compounds with selective antiplatelet activity without bleeding risks.
Innovation Solution
Development of sofalcone derivatives with modified chemical structures that act as TxA2 receptor antagonists, inhibiting platelet aggregation and thrombosis without affecting hemostatic function, thereby preventing thrombotic diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aspirin is used to inhibit platelet TxA2 synthesis, then antiplatelet effect is improved, but gastrointestinal ulcer and counteracting effect on vascular endothelial cells occur
Solution Approach 1:
The patent develops TxA2 receptor antagonists that selectively target platelet TxA2 receptors without affecting vascular endothelial cells. By achieving local selectivity for platelet-specific TxA2 receptors, the drug provides antiplatelet effect while avoiding the harmful effects on gastrointestinal cells and vascular endothelium that occur with aspirin's non-selective COX inhibition.
Solution Approach 2:
The patent uses TxA2 receptor antagonism as an intermediary mechanism to achieve antiplatelet effect. Instead of directly inhibiting TxA2 synthesis like aspirin, the drug blocks the TxA2 receptor on platelets, preventing TxA2 from binding to its receptor and triggering platelet activation. This intermediary approach allows selective antiplatelet activity without the broad COX inhibition side effects.
2Reliability
If existing TxA2 receptor antagonists are used, then selective antiplatelet activity is improved, but potency is insufficient for widespread clinical use
Solution Approach 1:
The patent modifies the chemical structure of TxA2 receptor antagonists by changing key parameters such as the R1-R6 substituent groups and n value in the core structure. These structural parameter changes result in compounds with enhanced binding affinity and potency at the TxA2 receptor, overcoming the limitation of existing antagonists while maintaining selective antiplatelet activity.
Data Source
AI summary
A series of sofalcone derivatives having the effect of inhibiting platelet aggregation and antithrombotic effect are disclosed. These sofalcone derivatives are antagonists of TxA2 receptor and have the effect of inhibiting platelet activation and aggregation without causing bleeding. In addition, a preparing method of the sofalcone derivatives and a method for preventing or treating thrombotic diseases or inhibiting platelet aggregation by administrating the sofalcone derivatives are also disclosed.